Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.4452W HIGH $21.36
Volume
968.61 K
Value Traded
5.46 M
Short % Float
6.34%
Days to Cover
3.6
+14.39%Week
+17.12%1 Month
+19.92%3 Month
+23.37%6 Month
-13.95%5 Year
-13.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.19 B
EPS (TTM)
-0.31
P/E Ratio
-
Ent. Value
11.71 B
Total Shares
357.04 M
Float Shares
40.09 M
Insiders
88.79%
Institutions
10.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BLCO Catalyst Timeline
Dated clinical, regulatory and corporate events for Bausch + Lomb Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bausch + Lomb Corporation
146Total events
5Upcoming
34Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
●PublicationPresentation
Publication of multinational survey results on burden of dry eye symptoms
dry eyesource ↗
▲Runway Guidance UpdateCorporate
Raises full-year 2026 revenue and Adjusted EBITDA excluding Acquired IPR&D guidance
●Management ChangeCorporate
Brent Saunders departs as Bausch + Lomb CEO by mutual agreement with the Board
▲FDA Feedback ReceivedBL1243FDA Meeting
FDA meeting provides clarity on BL1243 clinical development path for dry AMD
dry age-related macular degeneration (AMD)source ↗
▲Product LaunchScoutProPost-Market
ScoutPro, osmolarity test cards and control solutions available now through DryEye Rescue
dry eye diseasesource ↗
▲Partnership / LicenseScoutProCorporate
DryEye Rescue becomes exclusive U.S. distributor of ScoutPro
dry eye diseasesource ↗
▲EU ApprovalSeeLyraApprovedEx-US Regulatory
European CE Mark approval of SeeLyra femtosecond laser
laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeriessource ↗
▲PublicationPresentation
Publication of real-world study on enVista Aspire and enVista Aspire toric IOLs in Ophthalmology and Therapy
cataractsource ↗
●Management ChangeCorporate
Thomas J. Appio appointed chairman of the Bausch + Lomb Board of Directors
◆Topline ReadoutClinical Data
Topline results from pivotal study of enVista Beyond IOL reported
cataractsource ↗
▼Topline ReadoutBL1107 Low doseClinical Data
Phase 2 topline results for BL1107 in glaucoma
glaucomasource ↗
▼Program DiscontinuationBL1107 Low doseCorporate
Discontinuation of BL1107 development
glaucomasource ↗
▲Oral PresentationPresentation
Presentation of data showing addressing dry eye symptoms improves quality of life, including lower anxiety and increased self-confidence
dry eyesource ↗
●Timing GuidancePresentation
Several potential first-in-class pipeline assets expected to reach clinical and regulatory milestones
▲PublicationtonabersatPresentation
Ophthalmology Science publication of oral tonabersat 80 mg DME study
diabetic macular edemasource ↗
●Enrollment UpdateTrial
Trial recruitment for dual-action therapeutic (dry eye disease) on schedule
dry eye diseasesource ↗
▲Product LaunchSeeLyraApprovedPost-Market
Limited availability of SeeLyra in Europe
premium cataract, LASIK flap and corneal therapeutic surgeriessource ↗
▲Topline ReadoutLumifyApprovedClinical Data
Next-gen LUMIFY Phase 3 study met all primary and secondary endpoints
ocular rednesssource ↗
▲Trial Initiationbioactive lensTrial
Initiated enrollment for bioactive lens clinical study
not specifiedsource ↗
▲Trial Initiationnext-gen lifitegrastTrial
Initiated enrollment for next-gen lifitegrast clinical study
dry eyesource ↗
▲Trial InitiationTrial
Initiated enrollment for ocular surface pain clinical study
ocular surface painsource ↗
▲Supply DisruptionenVistaCMC / Inspection
Resumed full production of enVista platform IOLs after voluntary recall
cataract surgerysource ↗
▲Product LaunchenVistaPost-Market
Return to market of enVista intraocular lenses following voluntary recall
cataract surgerysource ↗
▲Full ResultsMIEBOApprovedClinical Data
Phase 4 data demonstrates rapid relief from dry eye symptoms
dry eye diseasesource ↗
▼Supply DisruptionenVistaCMC / Inspection
Voluntary recall of certain enVista intraocular lenses
cataract surgerysource ↗
Past FDA Catalysts and PDUFA Decisions
How BLCO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-04-19 | Lumify Preservative Free (brimonidine tartrate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 26%
Small Cap(rank 176 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BL1332 Small moleculeNCT06978244 | Ocular Pain | Phase 1 | ACTIVE NOT_RECRUITING | 24 | Nov 1, 2026 | ||||||
| WB007 0.05% Small moleculeCompletedNCT04149899 | Glaucoma, Primary Open Angle | Phase 1/2 | COMPLETED | 77 | Dec 14, 2022 | ||||||
| BTOS-HA Small moleculeCompletedNCT06803654 | Ocular Redness | Phase 3 | COMPLETED | 578 | Jun 29, 2025 | ||||||
| BL1332 Small moleculeCompletedNCT07412496 | Pain, Postoperative | Phase 2 | COMPLETED | 130 | Oct 4, 2026 | ||||||
| Brimonidine 0.025%/ Ketotifen 0.035% Small moleculeCompletedNCT05579730 | Allergic Conjunctivitis | Phase 3 | COMPLETED | 700 | Jul 22, 2023 | ||||||
| Brimonidine 0.025%/ Ketotifen 0.035% Small moleculeCompletedNCT05591755 | Seasonal Allergic Conjunctivitis | Phase 3 | COMPLETED | 229 | Aug 9, 2023 | ||||||
| Bepreve Small moleculeMarketedNCT00424398 | Allergic Conjunctivitis | Approved | COMPLETED | 1,098 | - | ||||||
| Loteprednol Etabonate Small moleculeMarketedNCT01996839 | Inflammation | Approved | COMPLETED | 1,653 | Jul 1, 2014 | ||||||
| bromfenac Small moleculeMarketedNCT00333918 | Pain | Approved | COMPLETED | 1,261 | Mar 1, 2007 | ||||||
| Besivance Treatment Group Small moleculeMarketedNCT01175590 | Bacterial Conjunctivitis | Approved | COMPLETED | 518 | Feb 1, 2012 | ||||||
| Vitrase Small moleculeNot countedNCT00198484 | Pain | Phase 3 | COMPLETED | 108 | Feb 1, 2005 | ||||||
| enVista UnknownCompletedNCT01230060 | Aphakia | Phase 3 | COMPLETED | 122 | Aug 1, 2011 | ||||||
| Loteprednol and tobramycin Small moleculeMarketedNCT01028027 | Conjunctivitis | Approved | COMPLETED | 357 | Mar 1, 2010 | ||||||
| Bromfenac A Small moleculeNot countedNCT01212471 | Dry Eye Syndrome | Phase 3 | COMPLETED | 840 | Dec 1, 2011 | ||||||
| Ketotifen/naphazoline Small moleculeNot countedNCT00770133 | Allergic Conjunctivitis | Phase 3 | COMPLETED | 285 | Jun 1, 2010 | ||||||
| Brimonidine 0.025% preservative-free formulation Small moleculeMarketedNCT05360784 | Ocular Redness | Approved | COMPLETED | 380 | Nov 23, 2022 | ||||||
| 0.5% Loteprednol Etabonate Small moleculeMarketedNCT00645671 | Ocular Inflammation | Approved | COMPLETED | 400 | Mar 1, 2009 | ||||||
| NOV03 Small moleculeMarketedNCT04567329 | Dry Eye Disease | Approved | COMPLETED | 1,475 | Aug 30, 2021 | ||||||
| Loteprednol Etabonate Small moleculeNot countedNCT02786901 | Cataract | Phase 3 | COMPLETED | 707 | Jul 1, 2017 | ||||||
| Loteprednol Etabonate Small moleculeMarketedNCT01435460 | Seasonal Allergic Conjunctivitis | Approved | COMPLETED | 300 | May 1, 2011 | ||||||
| Loteprednol Etabonate Small moleculeMarketedNCT00699153 | Ocular Inflammation | Approved | COMPLETED | 400 | Jun 1, 2009 | ||||||
| bromfenac Small moleculeNot countedNCT00423007 | Allergic Conjunctivitis | Phase 3 | COMPLETED | 90 | Aug 1, 2007 | ||||||
| bromfenac Small moleculeNot countedNCT00198445 | Postoperative Complications | Phase 3 | COMPLETED | 527 | Jan 1, 2004 | ||||||
| bromfenac Small moleculeMarketedNCT00703781 | Cataract | Approved | COMPLETED | 282 | - | ||||||
| ISV-403 Small moleculeMarketedNCT00347932 | Acute Bacterial Conjunctivitis | Approved | COMPLETED | 957 | Nov 1, 2007 |
Clinical Trial Results
Readouts, endpoints and source filings for every BLCO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Munsch FrederickOfficer (SVP, Controller and CAO) | Sell | -52,900 45,831 held | $16.78 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BLCO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % (-25 %) | 6.70 M | 444.47 K | -19.19% ( -105.53 K) |
Ownership Trends
BLCO Short Interest
Shares sold short, counted twice a month.
6.34%
Short % of Float
of tradable shares sold short
2.5M
Shares Sold Short
-14.0% vs prior count
3.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
705.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BLCO ranks across every disease it competes in
Competitive Position is a premium feature
See how BLCO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBLCO News
BLCOBausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
Bausch + Lomb published results from a multinational survey on dry eye symptoms. The survey indicated that self-reported symptoms were more prevalent than diagnoses by healthcare professionals. This highlights a significant gap in awareness and education regarding dry eye among patients and providers.
Read more →BLCO▲ +15.8%on this newsshared move
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Bausch + Lomb reported a strong third-quarter performance for 2026, with revenues of $1.375 billion, a 7% increase from the previous year. The company also raised its full-year guidance for revenue and adjusted EBITDA, reflecting growth across all segments. Notably, MIEBO and LUMIFY brands showed significant revenue increases, contributing to overall profitability.
Read more →BLCO▼ -7.1%on this news
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch + Lomb Corporation has appointed Thomas J. Appio as interim CEO, effective immediately. Appio, who is also the CEO of Bausch Health, will lead Bausch + Lomb while continuing his role at the parent company. The announcement comes with expectations to raise full-year 2026 guidance, suggesting a positive outlook for the company.
Read more →BLCOBausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Bausch + Lomb Corporation announced advancements in the development of BL1243, an oral treatment for dry age-related macular degeneration (AMD). This follows a constructive meeting with the FDA, which provided clarity on the clinical development path for the investigational drug. The progress is seen as a positive step towards addressing this condition.
Read more →BLCOBausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
Bausch + Lomb Corporation will release its third-quarter financial results on October 28, 2026. The company plans to host a conference call and live webcast at 8 a.m. ET to discuss these results and provide a business update. All relevant materials will be available on their Investor Relations website prior to the event.
Read more →BLCODryEye Rescue Becomes Exclusive U.S. Distributor of ScoutPro by Bausch + Lomb
DryEye Rescue has become the exclusive distributor of ScoutPro in the U.S., enhancing its collaboration with Bausch + Lomb. ScoutPro, an osmolarity test for diagnosing dry eye disease, is now available through DryEye Rescue. The test is portable, quick, and requires only a small tear sample, making it suitable for various clinical settings.
Read more →BLCOBausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
Bausch + Lomb has announced that its SeeLyra femtosecond laser has received CE Mark approval in Europe. This next-generation device is noted for its compact design and aims to enhance precision and control during various eye surgeries, including cataract and LASIK procedures. The approval marks a significant milestone for the company in expanding its product offerings in the eye health sector.
Read more →BLCOBausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Bausch + Lomb has published new research on the enVista Aspire and enVista Aspire toric intraocular lenses. The study, featured in the journal Ophthalmology and Therapy, indicates that these lenses provide good distance and functional intermediate vision. This research underscores the effectiveness of these enhanced monofocal lenses in real-world settings.
Read more →BLCOMost Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Bausch + Lomb released a survey revealing that many women are unaware that dry eye can be a symptom of perimenopause and menopause. Only 14% of respondents recognized this association, indicating a significant awareness gap. The findings aim to inform and educate women about this often-overlooked health issue.
Read more →BLCOBausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Bausch + Lomb Corporation has announced the advancement of two first-in-class eye health therapies into new trials following encouraging clinical results. CEO Brent Saunders emphasized the company's commitment to improving patient outcomes in eye health. This move reflects the company's ongoing dedication to innovation in the field.
Read more →BLCOBausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
Bausch + Lomb Corporation has announced updates to its Board of Directors at the request of its majority owner, Bausch Health Companies Inc. The company reaffirms its guidance, suggesting a positive outlook for its operations. Bausch Health holds approximately 87% ownership in Bausch + Lomb, reflecting strong backing for the eye health company.
Read more →BLCOBausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
Bausch + Lomb Corporation reported strong financial results for the second quarter of 2026, highlighting broad-based revenue growth and margin expansion. The company emphasized its ongoing progress in executing its three-year growth plan, which was initially presented at the Investor Day last November. The positive performance indicates effective management and operational improvements.
Read more →BLCOBausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
Bausch + Lomb Corporation has announced the launch of its EyeGility™ Inserter preloaded IOL delivery system in the United States. This new system is designed to enhance the surgical experience for eye surgeons and is part of the enVista IOL platform, known for its glistening-free optic. The product aims to meet the diverse needs of patients.
Read more →BLCOBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Bausch + Lomb Corporation announced topline results from its Phase 2 study of BL1107 for glaucoma. The study failed to meet its primary endpoint, as it could not replicate the visual function improvements seen in a previous Phase 1/2a study after 28 days of treatment. This outcome raises concerns about the efficacy of the candidate.
Read more →BLCOBausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
Bausch + Lomb has launched Orphia™, an AI-driven digital health platform aimed at streamlining tools for eye care providers. This initiative allows physicians to focus more on patient care rather than managing various disconnected technologies. The platform is designed to be inclusive for all eye care professionals, enhancing overall service delivery.
Read more →BLCOBausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
Bausch + Lomb is set to announce its financial results for the second quarter of 2026 on July 29. The announcement will provide insights into the company's performance during this period. Investors and stakeholders are likely to pay close attention to the results for future projections.
Read more →BLCONew Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
Bausch + Lomb has released new data indicating that effectively addressing dry eye symptoms can significantly enhance patients' quality of life. The findings suggest a correlation between symptom management and reduced anxiety, as well as increased self-confidence. This highlights the importance of treating dry eye conditions.
Read more →BLCOBausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
Bausch + Lomb Corporation reported strong first-quarter 2026 results with revenue reaching $1.244 billion, reflecting a 9% growth compared to the previous year. The company attributed its performance to robust sales in key areas, particularly in Pharmaceuticals. As a result, they have raised their full-year revenue and adjusted EBITDA guidance due to anticipated stronger business performance. However, they recorded a GAAP net loss of $71 million, although this was an improvement from the previous year's loss. The ongoing use of non-GAAP measures for analysis highlights their focus on operational efficiencies and revenue generation.
Read more →BLCOBausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
Bausch + Lomb Corporation reported its fourth-quarter and full-year financial results for 2025, showcasing significant revenue growth across several segments. The company achieved an impressive EBITDA margin expansion and increased revenues in dry eye products and Vision Care. However, despite these successes, Bausch + Lomb faced a GAAP net loss of $58 million in the fourth quarter and a total net loss of $360 million for the year. The company remains focused on its financial targets and operational improvements.
Read more →BLCOBausch + Lomb Completes Refinancing of Outstanding
Bausch + Lomb Corporation has successfully refined its credit agreement, resulting in a new tranche of $2.8 billion term B loans. This refinancing enables Bausch + Lomb to clear its outstanding term B loans due in 2028 and 2031, while securing lower interest margins. The amortization rate for the new loans is 1.00%, and the first installment is due by June 30, 2026. This move reflects the company's ongoing commitment to enhancing cash flow and maintaining a strong position in the eye health market.
Read more →About Bausch + Lomb Corporation
Headquarters520 APPLEWOOD CRESCENT, VAUGHAN, A6, L4K 4B4
BIOPHARMAWATCH ELITE PLUS
Trade the next BLCO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime